tetano
Editor, Senior Moderator
PLoS One
. 2022 Jun 30;17(6):e0269563.
doi: 10.1371/journal.pone.0269563. eCollection 2022.
Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening
Kamonpan Sanachai[SUP] 1 [/SUP], Tuanjai Somboon[SUP] 2 [/SUP], Patcharin Wilasluck[SUP] 3 4 [/SUP], Peerapon Deetanya[SUP] 3 4 [/SUP], Peter Wolschann[SUP] 5 6 [/SUP], Thierry Langer[SUP] 5 [/SUP], Vannajan Sanghiran Lee[SUP] 7 [/SUP], Kittikhun Wangkanont[SUP] 3 4 [/SUP], Thanyada Rungrotmongkol[SUP] 2 8 [/SUP], Supot Hannongbua[SUP] 1 [/SUP]
Affiliations
Abstract
SARS-CoV-2 causes the current global pandemic coronavirus disease 2019. Widely-available effective drugs could be a critical factor in halting the pandemic. The main protease (3CLpro) plays a vital role in viral replication; therefore, it is of great interest to find inhibitors for this enzyme. We applied the combination of virtual screening based on molecular docking derived from the crystal structure of the peptidomimetic inhibitors (N3, 13b, and 11a), and experimental verification revealed FDA-approved drugs that could inhibit the 3CLpro of SARS-CoV-2. Three drugs were selected using the binding energy criteria and subsequently performed the 3CLpro inhibition by enzyme-based assay. In addition, six common drugs were also chosen to study the 3CLpro inhibition. Among these compounds, lapatinib showed high efficiency of 3CLpro inhibition (IC50 value of 35 ± 1 μM and Ki of 23 ± 1 μM). The binding behavior of lapatinib against 3CLpro was elucidated by molecular dynamics simulations. This drug could well bind with 3CLpro residues in the five subsites S1', S1, S2, S3, and S4. Moreover, lapatinib's key chemical pharmacophore features toward SAR-CoV-2 3CLpro shared important HBD and HBA with potent peptidomimetic inhibitors. The rational design of lapatinib was subsequently carried out using the obtained results. Our discovery provides an effective repurposed drug and its newly designed analogs to inhibit SARS-CoV-2 3CLpro.
. 2022 Jun 30;17(6):e0269563.
doi: 10.1371/journal.pone.0269563. eCollection 2022.
Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening
Kamonpan Sanachai[SUP] 1 [/SUP], Tuanjai Somboon[SUP] 2 [/SUP], Patcharin Wilasluck[SUP] 3 4 [/SUP], Peerapon Deetanya[SUP] 3 4 [/SUP], Peter Wolschann[SUP] 5 6 [/SUP], Thierry Langer[SUP] 5 [/SUP], Vannajan Sanghiran Lee[SUP] 7 [/SUP], Kittikhun Wangkanont[SUP] 3 4 [/SUP], Thanyada Rungrotmongkol[SUP] 2 8 [/SUP], Supot Hannongbua[SUP] 1 [/SUP]
Affiliations
- PMID: 35771802
- DOI: 10.1371/journal.pone.0269563
Abstract
SARS-CoV-2 causes the current global pandemic coronavirus disease 2019. Widely-available effective drugs could be a critical factor in halting the pandemic. The main protease (3CLpro) plays a vital role in viral replication; therefore, it is of great interest to find inhibitors for this enzyme. We applied the combination of virtual screening based on molecular docking derived from the crystal structure of the peptidomimetic inhibitors (N3, 13b, and 11a), and experimental verification revealed FDA-approved drugs that could inhibit the 3CLpro of SARS-CoV-2. Three drugs were selected using the binding energy criteria and subsequently performed the 3CLpro inhibition by enzyme-based assay. In addition, six common drugs were also chosen to study the 3CLpro inhibition. Among these compounds, lapatinib showed high efficiency of 3CLpro inhibition (IC50 value of 35 ± 1 μM and Ki of 23 ± 1 μM). The binding behavior of lapatinib against 3CLpro was elucidated by molecular dynamics simulations. This drug could well bind with 3CLpro residues in the five subsites S1', S1, S2, S3, and S4. Moreover, lapatinib's key chemical pharmacophore features toward SAR-CoV-2 3CLpro shared important HBD and HBA with potent peptidomimetic inhibitors. The rational design of lapatinib was subsequently carried out using the obtained results. Our discovery provides an effective repurposed drug and its newly designed analogs to inhibit SARS-CoV-2 3CLpro.